AA
IONS icon

AlphaCentric Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

AlphaCentric Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
19,587
+1,064
+6% +$84K 1.47% 8
2025
Q4 		$1.47M Buy
+18,523
New +$1.39M 1.46% 10
2024
Q4 		$266K Buy
+7,614
New +$285K 0.27% 98

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCentric Advisors's IONS Position: Q1 2026 in Review

AlphaCentric Advisors increased its Ionis Pharmaceuticals (IONS) stake by 5.7% in Q1 2026, buying an estimated $84K and bringing the position to 19,587 shares worth $1.47M. The position accounts for 1.47% of the portfolio, ranked #8.

AlphaCentric Advisors first reported a position in IONS in Q4 2024 and has held it in 3 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • AlphaCentric Advisors held 19,587 shares of Ionis Pharmaceuticals worth $1.47M as of Q1 2026.
  • AlphaCentric Advisors bought 1,064 Ionis Pharmaceuticals shares in Q1 2026, an estimated $84K.
  • Ionis Pharmaceuticals made up 1.47% of AlphaCentric Advisors's portfolio in Q1 2026, its #8 holding.
  • AlphaCentric Advisors first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.